Overview

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Status:
Active, not recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of D-0316 versus Icotinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with locally advanced or Metastatic Non Small Cell Lung Cancer (NSCLC).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.